Todor Jeliaskov Appointed CEO of inHEART

inHEART, the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO. He will lead the French company in its mission to bridge the gap between cardiology and medical imaging with a digital twin of the patient’s heart. Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.

“I am thrilled to welcome Todor as our new CEO,” said Jean-Marc Peyrat, co-founder of inHEART. “His proven leadership and experience perfectly complement our existing team to scale up the company and to support its ambition to be a major player in the double-digit growing market of cardiac electrophysiology.”

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation of ultrasound imaging technology for cardiac interventions – 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound, the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.

“I am honored to join the exceptionally talented inHEART team that developed a unique solution for the guidance of cardiac ablations. It is rare to see new technologies with such a substantial impact on patient care.” said Todor Jeliaskov. “I am excited to be part of this revolution and I look forward to driving its international deployment to make it accessible to most patients.”

“At Elaia, we congratulate Todor Jeliaskov on his selection as Chief Executive Officer, we’re excited by the tremendous progress inHEART has made since Elaia’s investment in 2020 under Jean-Marc Peyrat’s leadership as CEO and would like to thank him and welcome him as the new Chief Technology Officer of the company,” said Samantha Jérusalmy, Partner at Elaia. “We are confident that inHEART is poised for strong growth and Todor’s commercial leadership and management experience are unique assets in this new phase.” explains Sacha Loiseau, Venture Partner at Elaia.

SourceinHEART

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”